TSTakato Sasaki

Takato Sasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takato Sasaki has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Upfront Cytoreductive Surgery as a Bridge to Systemic Therapy for Recurrent Peritoneal Dissemination of Ovarian Angiosarcoma: A Pediatric Case Report

    by Masanaga Matsumoto, Takato Sasaki, Yudai Goto, Toko Shinkai, Hiroko Fukushima, Hidetoshi Takada, Ayumi Shikama, Yusuke Kobayashi, Daisuke Miyazawa, Mari Watanabe, et al.

    INTRODUCTION: Ovarian angiosarcoma is exceptionally rare, especially considering those few pediatric cases that have been reported, and displays a poor outcome. Recurrent peritoneal dissemination of ovarian angiosarcoma is generally managed with systemic therapy, but refractory malignant ascites may compromise performance status and hinder treatment delivery. Herein, we report a pediatric case in which upfront cytoreductive surgery (CRS) controlled refractory ascites and enabled subsequent systemic therapy for recurrent peritoneal dissemination.CASE PRESENTATION: A 14-year-old girl presented with acute abdominal pain and underwent left salpingo-oophorectomy for a large ovarian tumor. Histopathological examination revealed mucinous carcinoma occupying most of the mass, with focal areas containing angiosarcoma and mature teratoma components. Staging surgery 1 month later showed no residual malignancy, and no adjuvant chemotherapy was administered. Six months after the initial surgery, she developed diffuse peritoneal dissemination and massive hemorrhagic ascites. Paracentesis provided only transient relief; ascites rapidly reaccumulated, oral intake became impossible, and progressive anemia required daily red blood cell transfusions for 6 consecutive days. Cell-block cytology of ascitic fluid suggested angiosarcoma. As adequate ascites control was not achievable and chemotherapy was considered impracticable, upfront CRS was performed, consisting of a total hysterectomy with right salpingo-oophorectomy and debulking of peritoneal dissemination. Resected lesions were exclusively composed of angiosarcoma. Postoperatively, the ascites markedly decreased, enabling the initiation of chemotherapy on POD 7 and completion of adjuvant chemoradiotherapy without substantial interruption. The patient has remained free of radiologic disease and ascites for 1 year after the initial surgery.CONCLUSIONS: This report demonstrated that CRS could provide effective control of malignant hemorrhagic ascites in recurrent peritoneal dissemination of ovarian angiosarcoma. Upfront CRS can be considered as a potential initial treatment option, facilitating the timely delivery and completion of subsequent systemic therapy.

  • Open Access

    Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study

    by Kouji Masumoto, Mitsuru Muto, Takato Sasaki, Mitsuhiro Shikamura, Tomoko Tanaka, Sho Sakui, Masakazu Miyamoto, Hiroya Nakano, Taisuke Kondo, Satoshi Ieiri

    Background: Patients with short bowel syndrome (SBS)‐associated intestinal failure (SBS‐IF) are dependent on parenteral support (PS). In Japan, teduglutide is the only GLP‐2 analog medicine indicated for these patients. There are limited data for pediatric patients, especially those with a low body weight. This study evaluated the safety and efficacy of teduglutide in Japanese pediatric patients with SBS‐IF (dependence on PS to provide ≥30% of fluid or caloric intake needs) who weighed less than 10 kg. Methods: This phase 3, open‐label study enrolled Japanese pediatric patients with SBS‐IF. Patients weighing less than 10 kg received teduglutide 0.05 mg/kg/day subcutaneously in 28‐week treatment cycles (24 weeks of teduglutide treatment and 4 weeks of follow‐up). Adverse events, changes in PS requirements, and growth parameters were assessed. Results: Three patients completed the study, with a mean teduglutide exposure duration of 48.9 weeks. All patients experienced treatment‐emergent adverse events (TEAEs), but none were related to the study drug or led to death or treatment discontinuation. Clinically meaningful reductions in mean PS volume (13.1%) and mean PS caloric intake (46.6%) were observed at the end of treatment from baseline. One patient achieved a reduction in PS volume of ≥20% at the end of treatment from baseline. Growth parameters showed increases in weight and height/length‐for‐age z ‐scores at the end of treatment from baseline. Conclusion: In the three patients with SBS‐IF who weighed less than 10 kg, no new safety signals were observed following teduglutide treatment. Clinically meaningful reductions in PS were noted and there was no adverse impact on growth parameters. Trial Registration: ClinicalTrials.gov registration number: NCT05027308


  • Open Access

    Real-Time Ultrasound-Guided Transurethral Incision for Posterior Urethral Valves

    by Yudai Goto, Kouji Masumoto, Takato Sasaki, Yasuhisa Urita, Kazuki Shirane, Katsuhiko Ueoka

    Background/Objectives: Transurethral incision (TUI) is a common procedure for posterior urethral valves (PUV). However, no standardized method has been established to assess its efficacy intraoperatively. In this study, we aimed to develop and evaluate a real-time ultrasound-guided TUI (RUG-TUI) technique. Methods: A single-center, retrospective feasibility study with a cohort design was conducted using historical controls to compare RUG-TUI with standard TUI in children with PUV. Data from patients who underwent RUG-TUI for PUV between April 2021 and July 2022 or TUI without real-time ultrasound guidance between August 2020 and March 2021 (control group) were retrospectively reviewed. A transperineal linear probe provided longitudinal imaging. The diameters of the constricted (C) and expanded (E) portions of the urethra before and after the procedure were measured, and the E/C ratio was calculated. The primary outcome was the duration of postoperative gross hematuria, and the secondary outcomes included changes in the urethral diameter ratio (E/C ratio), intraoperative complications, and residual obstruction on VCUG. Results: The mean duration of post-procedure macroscopic hematuria was significantly shorter in the RUG-TUI group than in the control group (p = 0.049). No massive intraoperative bleeding or sphincter damage occurred. In the RUG-TUI group, the mean diameters of the constricted segment before and after the procedure were 3.0 (±1.0) and 5.7 (±1.2) mm, respectively, while the pre- and postoperative E/C ratios were 1.8 (±0.5) and 0.9 (±0.1), respectively (p < 0.0001). Conclusions: RUG-TUI for PUV enabled visualization of the longitudinal axis of the urethra, allowing assessment of the anatomical relationship between the stenosis and external urethral sphincter. In this retrospective feasibility cohort, RUG-TUI was associated with a shorter duration of postoperative gross hematuria. These exploratory findings suggest that RUG-TUI may support intraoperative evaluation of procedural adequacy.


  • Open Access

    Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine

    by Yudai Goto, Kouji Masumoto, Takato Sasaki, Kazuki Shirane, Tomohiro Aoyama, Naoya Sakamoto, Takahiro Jimbo

    Background/Objectives: Short bowel syndrome (SBS) is the leading cause of pediatric intestinal failure. Plasma citrulline is considered a marker indicating an enterocyte volume and may help evaluate the response to teduglutide; however, this interpretation may vary depending on the remnant bowel anatomy. Methods: We conducted a retrospective case series of four pediatric patients with SBS (aged < 15 years) who received teduglutide for 12 months at our hospital between 2018 and 2023. Changes in plasma citrulline levels and parenteral nutrition requirements were assessed in addition to bowel anatomy classification. Results: This study included two males and two females. All patients showed an increase in plasma citrulline levels and a reduction in the requirement for parenteral nutrition (PN) after 12 months of teduglutide treatment. In SBS type 2 (jejunocolic anastomosis), citrulline levels increased by 114% and 52%, with PN reduction rates of 100% and 30%, respectively. In SBS type 3 (jejunoileal anastomosis), citrulline levels increased by 13.6% and 34%, with PN reductions of 33% and 73%, respectively. Conclusions: Teduglutide treatment increased plasma citrulline levels and reduced PN levels in all cases. However, the magnitude of the citrulline change varied across bowel anatomy types, suggesting that the anatomical difference in the remnant bowel may influence the biomarker response. Further detailed pediatric cases are required to clarify the role of citrulline in evaluating GLP-2 analogue treatment outcomes.


  • Open Access

    Rare anorectal malformations with long perineal fistula extending to the penile skin or scrotum: Clinical features and surgical pitfalls from a case series

    by Kazuki Shirane, Toko Shinkai, Hinako Sakai, Tomohiro Aoyama, Yudai Goto, Takato Sasaki, Naoya Sakamoto, Takahiro Jimbo, Yasuhisa Urita, Kouji Masumoto


  • Open Access

    Clinicopathological and genomic analysis of pediatric pheochromocytoma and sympathetic paraganglioma

    by Noriko Kimura, Koji Muroya, Masato Yonamine, Kazuhiro Takekoshi, Takeshi Sato, Rei Hirose, Takato Sasaki, Kana Tamai, Hiroyo Mabe, Junji Kawashima, et al.

    Pediatric patients with pheochromocytoma (PCC)/paraganglioma (PGL) (PPGL) are rare, and clinicopathological investigations, especially the relationship between gene analysis and histological features, are insufficient. We comprehensively examined the clinical data, germline/somatic variants (mutations), and pathological characteristics of operated tumors using immunohistochemical expression and histological grading by Grading of Adrenal PCC and PGL score. This study included 28 patients (15 males and 13 females) aged <19 years. The age at the diagnosis was 12.8 ± 4.5 years. The included patient often had multiple PPGLs, with 39 tumors, including 21 PCCs and 18 PGLs, with average tumor sizes of 45.0 ± 22.8 and 42.6 ± 23.6 mm, respectively. Genomic types examined by gene mutations and immunohistochemistry of CA9 for VHL, SDHB for SDHx, and MAX for MAX, classified them into 14 VHL (50%), ten SDHx (35.7%), one MAX (3.6%), and three unknown (10.7%) types. Tumor metastasis was limited to two SDHB-related PPGLs, but not to VHL-related PPGLs. In both patients, the metastatic sites were the bones. The average GAPP score of the PPGLs was 2.9 ± 1.5 in VHL and 5.3 ± 1.7 in SDHB, and histological grades were well-differentiated in VHL and moderately differentiated in SDHB. SSTR2 expression was positive in 90% of SDHB-related PPGLs, but negative in 75% and weakly or focally positive in 25% of VHL-related PPGLs. Most pediatric PPGLs (90%) demonstrated mutations in VHL, SDHB, and MAX, with histological features depending on the mutation type. Combined genetic and immunohistochemical examination is desirable for accurate genomic diagnosis, and clinicopathological study.


  • Open Access

    Analysis of the changes in intestinal lipid absorption after small bowel resection in mice

    by Takato Sasaki, Kouji Masumoto, Kentarou Ono, Yudai Goto, Yoshimi Nakagawa, Hitoshi Shimano

    Purpose Prolonged lipid malabsorption occurs after small bowel resection (SBR). We aimed to clarify the underlying mechanism using a mouse model. Methods SBR mice were created by resecting 50% of the proximal intestine. In sham mice, the intestine was transected and re-anastomosed. Intravenous nutrition was not initiated and mice were fed a liquid elemental diet followed by a solid standard rodent diet for one week each. Animals were sacrificed on postoperative day (POD)7 or POD14, and the following data were analyzed: body weight, caloric intake, histopathological findings, and the mRNA expression of genes related to intestinal lipid absorption in the remnant intestines (jejunum and ileum). Results SBR group showed significantly delayed body weight recovery, despite comparable caloric intake. A histopathological examination revealed increased villus height and deepening crypts in the remnant jejunum and ileum as “morphological adaptation” after SBR. Importantly, huge differences in the mRNA expression of genes related to intestinal lipid absorption were observed between the remnant jejunum and ileum, and above differences were only slight changed after SBR on both POD7 and POD14. Conclusions Insufficient compensation of the gene expression related to intestinal lipid absorption might be the cause of prolonged lipid malabsorption after SBR.

  • Open Access

    Gallbladder cancer 20 years after surgery for duodenal atresia with biliary anomalies

    by Shunsuke Fujii, Kouji Masumoto, Takato Sasaki, Fumiko Chiba, Takahiro Jimbo, Yasuhisa Urita

  • Open Access

    Optimal First-Line Antibiotic Treatment for Pediatric Complicated Appendicitis Based on Peritoneal Fluid Culture

    by Tsubasa Aiyoshi, Kouji Masumoto, Nao Tanaka, Takato Sasaki, Fumiko Chiba, Kentaro Ono, Takahiro Jimbo, Yasuhisa Urita, Toko Shinkai, Hajime Takayasu, et al.

    Aiyoshi T, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 Nov;24(6):510-517. https://doi.org/10.5223/pghn.2021.24.6.510